Diabetes mellitus is a risk factor for muscle loss and sarcopenia. Sodium-glucose co-
transporter 2 inhibitors (SGLT2i) or “gliflozins” are one of the newest anti-hyperglycemic …

Objective Sarcopenia has been recognized as the third category of disabling complications
in patients with type 2 diabetes mellitus (T2DM), in addition to micro-and macrovascular …

Objective Type 2 diabetes mellitus (T2DM) is closely related to sarcopenic obesity (SO).
Body composition measurement including body weight, body mass index, waist …

Aim This study aims to assess the association between sodium–glucose cotransporter type-
2 inhibitor (SGLT-2i) treatment and muscle atrophy in patients with type 2 diabetes mellitus …

Body composition is related to cardiometabolic disorders and is a major driver of the
growing incidence of type 2 diabetes mellitus (T2DM). Altered fat distribution and decreased …

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are commonly used in the
management of type 2 diabetes mellitus (T2DM) and have been found to worsen the …

Background and Aims: It is currently unclear whether sodium–glucose co-transporter 2
(SGLT2) inhibitor administration can improve the insulin sensitivity as well as rapidly reduce …

There has been a concern that sodium–glucose cotransporter 2 (SGLT2) inhibitors could
reduce skeletal muscle mass and function. Here, we examine the effect of canagliflozin …

Diabetes mellitus is recognized as a risk factor for sarcopenia. Luseogliflozin, a selective
sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces inflammation and oxidative …

Several meta‐analyses have been conducted to evaluate the weight loss effect of sodium–
glucose cotransporter 2 (SGLT‐2) inhibitors in patients with type 2 diabetes, whereas pooled …